Inclusion Criteria:

          -  Male or female aged ≥ 18 years

          -  Metastatic colorectal cancer or head and neck squamous cell carcinoma

          -  c-MET positive (defined by c-MET IHC intensity score +2 in ≥ 50% of tumor cells and
             MET gene copy number ≥ 5 by FISH or IHC intensity score +3 in ≥ 50% of tumor cells)
             and K/NRAS WT status for mCRC patients only

          -  At least one previous line of treatment for the metastatic disease and the last
             treatment must have included cetuximab or panitumumab. Documentation of clinical
             benefit and subsequent progression on cetuximab or panitumumab as the most recent line
             of treatment is required for patients in the expansion part

          -  Measurable disease as per RECIST v1.1

          -  ECOG performance status ≤ 2

        Exclusion Criteria:

          -  Prior treatment with c-MET/HGF inhibitors

          -  History of severe reactions to cetuximab and/or panitumumab (except for G3 rash and G3
             hypomagnesaemia)

          -  History of acute or chronic pancreatitis

          -  Active bleeding within 4 weeks prior to screening visit

          -  Symptomatic brain metastases

          -  Feeding tube dependence

          -  Not adequate hematologic, renal and hepatic function